Private Companies
Psychedelic Training Provider Fluence Files Trademark for Common Phrase, Walks Back After Criticism
Fluence will no longer seek a trademark for the phrase “Psychedelic Harm Reduction and Integration.”
The post Psychedelic Training Provider Fluence…
Psychedelic Training Provider Fluence Files Trademark for Common Phrase, Walks Back After Criticism
Fluence will no longer seek a trademark for the phrase “Psychedelic Harm Reduction and Integration.”
Psymposia is a 501(c)(3) non-profit media organization that offers leftist perspectives on drugs, politics, and culture. We rely on contributions from our readers and listeners. Your support is vital to sustaining Psymposia.
Support Psymposia’s independent journalism on Patreon and help us drive the Mystery Machine! We’re a bunch of meddling kids who are unmasking the latest shenanigans on the psychedelics beat.
On October 2, 2022, psychedelic therapy training provider Fluence filed a trademark for the phrase “Psychedelic Harm Reduction and Integration.” In response to criticism of this decision, the organization has walked back their attempt to trademark the phrase.
When word spread about the attempted trademark, people online expressed surprise that Fluence would attempt to trademark such basic language. The terms “harm reduction” and “integration” are commonly used when discussing psychedelics and other drugs.
Harm reduction refers to practices, such as drug testing or having a trip sitter, which help lessen the chances of negative social and physical consequences of using drugs. Integration refers to intentional processing of emotions and experiences that come up while using a drug.
President of the Australian Psychedelic Society, Samuel Douglas, tweeted on October 26, “Everyone working in psychedelic harm reduction, give up and go home: @Fluencetraining has, apparently, trademarked ‘Psychedelic Harm Reduction and Integration’ – PHRI”. Douglas followed up with a note that the trademark appeared to still be pending.
It was not entirely clear that this trademark was pending, however, as Fluence had listed a certification course on its website called “Postgraduate Certificate in Psychedelic Harm Reduction and Integration”, which included the “” before the trademark was even filed in October.
Brad Burge, Fluence’s Director of Communication, claimed the trademark application was only intended to be used with Fluence’s specific training program and not intended to restrict others’ use of the terms “harm reduction” or “integration.”
“Fluence realizes [the trademark] may lead to confusion among practitioners who use these terms, or some combination of them, to describe their clinical practices,” Burge said. “Recognizing this, Fluence is in the process of revising its trademark application for a term with increased specificity and clarity.”
Why a training program composed of commonly used terms would require a trademark was not made explicit, but Burge followed up on November 1, stating, “As of today, Fluence has decided not to pursue a trademark for psychedelic harm reduction and integration as the name of its training program.”
The post Psychedelic Training Provider Fluence Files Trademark for Common Phrase, Walks Back After Criticism appeared first on Psymposia.
psychedelics psychedelic fluence research-
Psychedelics1 week ago
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Law & Regulation1 week ago
Going concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psilocybin1 week ago
Are Shrooms Legal in Oregon: Full Guide
-
Psychedelics1 week ago
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics1 week ago
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Psychedelics1 week ago
Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Law & Regulation1 week ago
Clearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psychedelics7 days ago
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product